Supplements / medicine · 8 Sept 2026
Paracetamol use during pregnancy is linked to changed reproductive development in daughters
Source: EurekAlert
What the research found
Study (observational). Denmark’s COPANA team led by Margit Bistrup Fischer (Rigshospitalet) reports that infant girls whose mothers used paracetamol in pregnancy had, at three months, about 40% smaller ovarian volume, 13% smaller uterine volume, 23% fewer ovarian follicles, and lower anti-Müllerian hormone after early-pregnancy exposure. Mothers used relatively low doses; none exceeded the 4,000 mg daily maximum, mostly for headache or musculoskeletal pain. This is not a trial proving harm at every dose, and untreated pain also carries risks. Do not start or stop a medicine in pregnancy without a clinician. Educational maternal-health notes, not medical advice.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34